Sponsors › Amgen
Amgen
Every GLP‑1 and incretin trial, approval and scheduled result we hold for Amgen, drawn from ClinicalTrials.gov and Drugs@FDA.
Amgen is a commercial sponsor with 13 trials in the incretin class on file here, all of maridebart cafraglutide. The programme is split between 3 early-stage trials and 10 in phase 3 or later. No approved FDA submission is recorded against this sponsor for these molecules, which is normal for a programme that has not reached the market. The next scheduled result is 2027-01-21.
- Molecules
- maridebart cafraglutide
- Trials on file
- 13
- Active trials
- 12
- Results scheduled
- 11
- Approved FDA submissions
- 0
Results due
Trials on file
All 13 incretin trials recorded for this sponsor, active first.